1. American Society of Clinical Oncology (2019) Guidelines by clinical area, gastrointestinal cancer. https://www.asco.org/research-guidelines/quality-guidelines/guidelines [Accessed: August 24, 2019].
2. Atashzar, M.R., Baharlou, R., Karami, J., Abdollahi, H., Rezaei, R., Pourramezan, F. & Zoljalali Moghaddam, S.H. (2020) Cancer stem cells: a review from origin to therapeutic implications. J. Cell. Physiol., 235, 790-803.
3. Basakran, N.S. (2015) CD44 as a potential diagnostic tumor marker. Saudi Med. J., 36, 273-279.
4. Bitaraf, S.M., Mahmoudian, R.A., Abbaszadegan, M., Mohseni Meybodi, A., Taghehchian, N., Mansouri, A., Forghanifard, M.M., Memar, B. & Gholamin, M. (2018) Association of two CD44 polymorphisms with clinical outcomes of gastric cancer patients. Asian Pac. J. Cancer Prev., 19, 1313-1318.
5. Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A. & Jemal, A. (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin., 68, 394-424.